This is expected and does not mean the medicine is not working
Human clinical-trial data (Phase 1/2 studies in wound healing, cardiac injury, and dry eye) exist only for a different, full-length recombinant thymosin beta-4 product, not for the short synthetic fragment marketed as TB-500, so no completed published human trial has evaluated TB-500 specifically for muscle, tendon, or joint recovery
Pillar 2: Delivery Precision Laser diffraction analysis verifies droplet size distribution and spray pattern consistency, ensuring each activation delivers the same research compound quantity and distribution
It has also been associated with reduced visible redness and discoloration, particularly in the context of photodamage
On July 23, the committee recommended that BPC-157 be moved to the list so that the peptide can be legally prescribed and compounded in the future
[ 5 ] Other human studies by researchers closely associated with DSIP's discovery reported more favorable results, including normalization of disturbed sleep following repeated injections